Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Pfizer Q1 profit up 9...

    Pfizer Q1 profit up 9 percent on higher drug sales, lower costs

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-02T09:07:23+05:30  |  Updated On 2 May 2019 9:07 AM IST
    Pfizer Q1 profit up 9 percent on higher drug sales, lower costs



    Pfizer modestly lifted its full-year profit forecast. The company also bought back $8.9 billion worth of shares in the first quarter, a jump from the year-ago period.


    New York: Pfizer reported higher first-quarter profits Tuesday, with stronger results in oncology and internal medicine offsetting a decline in sterile injectables.


    Net profits were $3.9 billion, up 9.1 per cent from the year-ago period.


    Revenues edged up 1.6 per cent to $13.1 billion.


    Read Also: Pfizer, GSK consumer healthcare venture to focus on China, US market


    Standout products included the blood thinner Eliquis and breast cancer drug Ibrance.


    Chief Executive Albert Bourla touted regulatory approvals of new drugs, including cancer treatments, along with other medicines that could be evaluated by government health officials over the course of 2019.


    "I believe our pipeline today represents an unprecedented opportunity to deliver a life-changing impact for millions of patients while enhancing value for all of our stakeholders," Bourla said.


    Read Also: Pfizer gets EU nod to VIZIMPRO for treating lung cancer


    Results were dented somewhat by a sales decline in Pfizer's "hospital" business in the United States, a newly-formed business unit that comprises sterile injectable and anti-infection medicines, some of which have seen sales erode due to competition from generics.


    The performance also weakened in rare disease drugs.


    The firm modestly lifted its full-year profit forecast. The company also bought back $8.9 billion worth of shares in the first quarter, a jump from the year-ago period.


    Read Also: Pfizer wins USFDA approval for IBRANCE to treat men with Metastatic Breast Cancer








    Albert Bourlablood thinner Eliquisbreast cancerbreast cancer drug Ibrancecancer treatmentsInternal MedicineNew YorkoncologyPfizerPfizer Q1Pfizer sharesq1 result pfizerrare disease drugsSterile Injectablessterile injection
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok